Harnessing AI For Drug Development – UK's BenevolentAI And MRCT Link
Executive Summary
The hope artificial intelligence can revolutionize current drug discovery methods will be tested in a new collaboration between UK-based BenevolentAI and the medical research charity MRC Technology.
You may also be interested in...
Quest To Use AI In Drug Discovery Joins Sanofi and Exscientia
Sanofi hopes to use Exscientia's artificial intelligence (AI) platform to develop bispecific-small-molecule drugs for diabetes and associated metabolic conditions.
Upsher-Smith buys UK's Proximagen for £223m plus CVR
Upsher-Smith Laboratories of the US is to buy the UK firm Proximagen for £223 million plus a potential £134 million through contingent value rights (CVRs) based on the success of two drugs in its pipeline.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.